BNC Korea Co., Ltd. (KOSDAQ:256840)

Market Cap	272.21B +2.6%
Revenue (ttm)	95.90B +7.5%
Net Income	2.84B -78.7%
EPS	42.00 -78.8%
Shares Out	68.39M
PE Ratio	94.76
Forward PE	n/a
Dividend	70.00 (1.74%)
Ex-Dividend Date	Dec 29, 2025

Volume	379,631
Average Volume	461,333
Open	4,095.00
Previous Close	4,090.00
Day's Range	3,975.00 - 4,110.00
52-Week Range	3,645.00 - 6,310.00
Beta	0.70
RSI	48.25
Earnings Date	Mar 27, 2026

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 250
• Stock Exchange: KOSDAQ
• Ticker Symbol: 256840

Financial Performance

In 2025, BNC Korea's revenue was 95.90 billion, an increase of 7.47% compared to the previous year's 89.23 billion. Earnings were 2.84 billion, a decrease of -78.68%.